

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (withdrawn): A human engineered anti-Ep-CAM antibody which binds specifically to human Ep-CAM comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 19 or SEQ ID NO: 21.

Claim 2 (withdrawn): A human engineered anti-Ep-CAM antibody which binds specifically to human Ep-CAM comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, or SEQ ID NO: 45.

Claim 3 (withdrawn): A human engineered anti-Ep-CAM antibody which specifically binds to human Ep-CAM comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6.

Claim 4 (withdrawn): A human engineered anti-Ep-CAM antibody of any one of claims 1 to 3 which is a full length antibody.

Claim 5 (withdrawn): A human engineered anti-Ep-CAM antibody of any one of claims 1 to 3 which is a human IgG. 6.

Claim 6 (withdrawn): A human engineered anti-Ep-CAM antibody of any one of claims 1 to 3 which is an antibody fragment.

Claim 7 (withdrawn): A human engineered anti-Ep-CAM antibody of claim 6 wherein the antibody fragment is a F(ab).sub.2, Fab, Fv or ScFv.

Claim 8 (withdrawn): A labeled antibody comprising the human engineered anti-Ep-CAM antibody of any one of claims 1 to 3 bound to a detectable label.

Claim 9 (withdrawn): An immobilized antibody comprising the human engineered anti-Ep-CAM antibody of any one of claims 1 to 3 bound to a solid phase.

Claim 10 (withdrawn): A conjugate comprising the human engineered anti-Ep-CAM antibody of any one of claims 1 to 3 bound to a cytotoxic or non-cytotoxic agent.

Claim 11 (withdrawn): A method for determining the presence of Ep-CAM protein comprising exposing a sample suspected of containing the Ep-CAM protein to the human engineered anti-Ep-CAM antibody of any one of claims 1 to 3 and determining binding of the antibody to the sample.

Claim 12 (withdrawn): A kit comprising the human engineered anti-Ep-CAM antibody of any one of claims 1 to 3 and instructions for using the human engineered anti-Ep-CAM antibody to detect the Ep-CAM protein.

Claim 13 (withdrawn): Isolated nucleic acid sequence encoding the Ep-CAM antibody of claim 1.

Claim 14 (withdrawn): Isolated nucleic acid sequence encoding the Ep-CAM antibody of claim 2.

Claim 15 (withdrawn): Isolated nucleic acid sequence encoding the Ep-CAM antibody of claim 3.

Claim 16 (withdrawn): A vector comprising the nucleic acid sequence of claim 13.

Claim 17 (withdrawn): A vector comprising the nucleic acid sequence of claim 14.

Claim 18 (withdrawn): A vector comprising the nucleic acid sequence of claim 15.

Claim 19 (withdrawn): A host cell comprising the nucleic acid sequence of claim 13.

Claim 20 (withdrawn): A host cell comprising the nucleic acid sequence of claim 14.

Claim 21 (withdrawn): A host cell comprising the nucleic acid sequence of claim 15.

Claim 22 (withdrawn): A process of producing human engineered anti-Ep-CAM antibody comprising culturing a host cell comprising the nucleic acid sequence of claim 13 so that the nucleic acid sequence is expressed.

Claim 23 (withdrawn): A process of producing human engineered anti-Ep-CAM antibody comprising culturing a host cell comprising the nucleic acid sequence of claim 14 so that the nucleic acid sequence is expressed.

Claim 24 (withdrawn): A process of producing human engineered anti-Ep-CAM antibody comprising culturing a host cell comprising the nucleic acid sequence of claim 15 so that the nucleic acid sequence is expressed.

Claim 25 (withdrawn): The process of claim 22 further comprising recovering the human engineered anti-Ep-CAM antibody from the host cell culture.

Claim 26 (withdrawn): The process of claim 23 further comprising recovering the human engineered anti-Ep-CAM antibody from the host cell culture.

Claim 27 (withdrawn): The process of claim 24 further comprising recovering the human engineered anti-Ep-CAM antibody from the host cell culture.

Claim 28 (withdrawn): A composition comprising the human engineered anti-Ep-CAM antibody of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 29 (withdrawn): A composition comprising the human engineered anti-Ep-CAM antibody of claim 2 and a pharmaceutically acceptable carrier or diluent.

Claim 30 (withdrawn): A composition comprising the human engineered anti-Ep-CAM antibody of claim 3 and a pharmaceutically acceptable carrier or diluent.

Claim 31 (currently amended): A method for treating a mammal suffering from an Ep CAM mediated disease, disorder or condition adenocarcinoma comprising administering to a mammal a pharmaceutically effective amount of the human engineered anti-Ep-CAM antibody that binds specifically to human Ep-CAM comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 19 and the light chain variable region comprising the amino acid sequence of SEQ ID NO: 6 of claim 1 to the mammal.

Claim 32 (currently amended): A method for treating a mammal suffering from an Ep CAM mediated disease, disorder or condition adenocarcinoma comprising administering to a mammal a pharmaceutically effective amount of the human engineered anti-Ep-CAM antibody that binds specifically to human Ep-CAM comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 21 and the light chain variable region comprising the amino acid sequence of SEQ ID NO: 8 of claim 2 to the mammal.

Claim 33 (canceled):

Claim 34 (original): The method of claim 31 further comprising administering a chemotherapeutic agent before, after or simultaneously with the human engineered anti-Ep-CAM antibody.

Claim 35 (original): The method of claim 32 further comprising administering a chemotherapeutic agent before, after or simultaneously with the human engineered anti-Ep-CAM antibody.

Claim 36 (canceled): The method of claim 33 further comprising administering a chemotherapeutic agent before, after or simultaneously with the human engineered anti-Ep-CAM antibody.

Claim 37 (withdrawn): A method for determining the presence of a human antibody made by a subject in response to administration to the subject of the human engineered anti-Ep-CAM antibody of any one of claims 1, 2 or 3 comprising exposing a sample suspected of containing the human antibody to the human engineered anti-Ep-CAM antibody and determining the binding of the human antibody to the sample.

Claim 38 (withdrawn): The method of claim 37 wherein the sample is blood, serum or plasma.